Clinical trials
Phase 2 Pulmonary Fibrosis trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
43 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2008 | 4 |
| 2010 | 3 |
| 2011 | 2 |
| 2013 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Terminated | 10 |
| Recruiting | 7 |
| Withdrawn | 3 |
| Active, not recruiting | 2 |
| Enrolling by invitation | 2 |
| Unknown status | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bellerophon | 2 |
| Celgene | 2 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
| Peter Caravan | 2 |
| PureTech | 2 |
| The Methodist Hospital Research Institute | 2 |
| Actelion | 1 |
| Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | 1 |
| Amgen | 1 |
| Aptabio Therapeutics, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pulmonary Fibrosis | 43 |
| Idiopathic Pulmonary Fibrosis | 21 |
| Lung Diseases, Interstitial | 14 |
| Hypertension, Pulmonary | 8 |
| Fibrosis | 7 |
| Lung Diseases | 6 |
| Idiopathic Interstitial Pneumonias | 5 |
| Respiratory Tract Diseases | 4 |
| COVID-19 | 3 |
| Chronic Cough | 2 |
Trials
Showing 1 to 25 of 43. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.